The cellular oncoprotein Ewing's sarcoma oncogene (EWS)/activating transcription factor 1 (ATF1) is a highly specific marker for malignant melanoma of soft parts (MMSP) and is a potent activator of several cAMP-inducible promoters, including the somatostatin promoter. Here we explored the potential for using the somatostatin promoter to direct toxic gene expression in MMSP cells. When introduced into MMSP cells, a somatostatin-herpes simplex virus thymidine kinase fusion gene confers strong and cell-specific sensitivity to the cytotoxic prodrug ganciclovir. Ganciclovir sensitivity requires the ATF-binding site present in the somatostatin promoter, indicating that toxic gene expression is caused by EWS/ATF1. We also tested the efficacy of recombinant adenoviruses adenoviruses for gene delivery and expression in two MMSP cell lines (DTC1 and Su-ccs-1). Surprisingly, several promoters (including somatostatin) that are strongly activated by EWS/ATF1 in transient assays are not activated in DTC1 and Su-ccs-1 cells when present in an adenovirus vector. In summary, our findings demonstrate the potential for using the somatostatin promoter for cytotoxic prodrug therapy for MMSP. However, first-generation adenovirus vectors cannot be used as promoter delivery vehicles for toxic gene expression in MMSP cells. Cancer Gene Therapy (2000) 7, 396 -406
C hromosomal translocations of the N-terminal region of the Ewing's sarcoma oncogene (EWS) to a variety of cellular transcription factors produces dominant oncogenes (EWS fusion proteins (EFPs)) that cause distinct sarcomas. 1, 2 In malignant melanoma of soft parts (MMSP), EWS is fused to activating transcription factor 1 (ATF1); 3 in Ewing's sarcoma, EWS is fused to the ETS domain family members; 4 -8 and in desmoplastic small round cell tumors, EWS is fused to the Wilm's tumor oncogene, WT1. 9 Because EFPs are strong transcriptional activators, it is thought that EFPinduced malignancies arise via aberrant gene activation, with the tumor type being specified by the EWS fusion partner.
MMSP (also known as clear cell sarcoma) is typically associated with tendons and aponeuroses and is thought to be of neuroectodermal origin. 10, 11 MMSP is a very aggressive, early onset tumor that initially grows slowly, resulting in 20% of patients having metastases at the time of diagnosis. 12 Current treatment involves surgery combined with chemotherapy and radiotherapy, 10,13 but recurrence is high and mortality is ϳ45% due to metastatic disease. The need for more effective therapy of MMSP and other EFP-related tumors is apparent and emerging gene therapy techniques may offer new approaches.
In the case of Ewing's sarcoma 5 and desmoplastic small round cell tumors 14 the oncogenic properties of EFPs have been demonstrated directly and deregulated target genes have been identified. [15] [16] [17] [18] [19] [20] Furthermore, in Ewing's sarcoma, agents that antagonize EWS-Fli1 fusion proteins can also inhibit cellular proliferation, [22] [23] [24] indicating the potential for the development of therapeutic agents that target EWS/Fli. In contrast to EWS/ Fli, the role that EWS/ATF1 plays in tumorigenesis is poorly characterized. Because ATF1 is a cAMP-inducible activator, 25, 26 it is predicted that EWS/ATF1 acts via constitutive activation of cAMP-inducible genes. However, the critical target genes have not yet been identified. In addition, a role for EWS/ATF1 in tumor maintenance has not yet been established. Consequently, it is not known whether therapeutic approaches aimed at antagonizing EWS/ATF1 will be applicable to MMSP.
An alternative therapeutic approach (cytotoxic prodrug therapy) for MMSP involves the exploitation of tumor-specific promoters to target tumor cells for the action of cytotoxic agents. [27] [28] [29] Previous studies have characterized EWS/ATF1 as a tumor-specific activator of promoters containing ATF-binding sites. 30 -32 Transcriptional activation is dependent upon the EWS activation domain (EAD) 30, 31 and the DNA-binding domain of ATF1. 30 -32 Most significantly, promoters that can be activated by EWS/ATF1 (e.g., the somatostatin promoter) are constitutively active when transiently introduced into tumor-derived cell lines (DTC1 and Su-ccs-1, hereafter referred to as MMSP cells) containing endogenous EWS/ATF1. 30 In addition to a cell-specific targeting agent (such as a tumor-specific promoter), cytotoxic prodrug treatment requires a safe and efficient vector to introduce the therapeutic gene and an effective prodrug. Among many available systems, recombinant adenoviruses (adenoviruss) 33, 34 and the herpes simplex virus thymidine kinase (hsvtk) gene have been well studied. The combined use of hsvtk as a toxic gene and adenovirus as a gene delivery vehicle has proven effective for prodrug sensitization of other tumor cell lines. [35] [36] [37] In the current study, we tested the use of a somatostatin promoter-hsvtk fusion gene and adenovirus vectors for cytotoxic prodrug treatment of MMSP cell lines. Our results demonstrate the potential of the somatostatin promoter and hsvtk as cytotoxic agents for MMSP cells. Surprisingly however, several promoters (including somatostatin) that are strongly activated in MMSP cells using plasmid-based transient assays are not activated when present in an adenovirus vector. Thus, first-generation adenovirus vectors cannot be used as promoter delivery vehicles for EWS/ATF1-dependent toxic gene expression in MMSP cells.
MATERIALS AND METHODS

Plasmids
p⌬(Ϫ71)SomCAT contains the somatostatin promoter at position Ϫ71, fused to the chloramphenicol acetyl transferase (CAT) coding sequences.
38 p⌬(Ϫ71)SomCAT contains a single ATF1-binding site, which is required for activation by both cAMP 38 and EWS/ATF1. 30 p⌬(Ϫ42)SomCAT is the same as p⌬(Ϫ71)SomCAT, except that sequences from position Ϫ71 to Ϫ42 of the somatostatin promoter are deleted. 30 Therefore, p⌬(Ϫ42)SomCAT lacks the ATF1-binding site of the somatostatin promoter.
30 p⌬(Ϫ42)SomTK and p⌬(Ϫ71)SomTK are identical with p⌬(Ϫ42)SomCAT and p⌬(Ϫ71)SomCAT, respectively, except that the CAT sequence is replaced by the cDNA sequence of hsvtk. pSVEA contains the complete EWS/ ATF1 coding sequence with 123 of 5 untranslated sequences from EWS and can express EWS/ATF1 under the control of the simian virus 40 (SV40) early promoter. pRSVCAT contains the Rous sarcoma virus (RSV) long terminal repeat linked to CAT, 39 and pCAT-TM-control (Promega, Madison, Wis) contains the SV40 enhancer and early promoter linked to CAT. pVIP25CAT 40 contains the vasoactive intestinal peptide (VIP) cAMP-responsive element containing two ATF-binding sites, fused to the RSV promoter from positions Ϫ50 to ϩ39 and to CAT. pVIP4CAT contains 240 bp of the VIP promoter, including the cAMP-responsive element linked to the reporter CAT gene. 40 pCAT-BstN1 (Ref. 41 , referred to as pE3CAT in Fig 2) contains the adenovirus E3 promoter to position Ϫ105 fused to CAT. p⌬E1(Ϫ71A) (used to construct AD71) was obtained by inserting a BamHI/AatII fragment from p⌬(Ϫ71A)SomCAT and an oligonucleotide to reconstruct the somatostatin promoter to position Ϫ71 into the multiple cloning site of p⌬E1SP1A. p⌬E1(Ϫ42A) (used to construct AD42) was obtained by insertion of an AatII/BamHI blunt fragment from p⌬(Ϫ71)SomCAT into the EcoRI/BamHI blunt sites of the multiple cloning region of p⌬E1sp1A. p⌬E1(25A) (used to construct AD25V) was obtained by inserting a BamHI/AflIII blunt fragment from pVIP25CAT into the EcoRI/BamHI blunt sites of p⌬E1sp1A. p⌬E1(VIPB) (used to construct ADVIP) was obtained by inserting a SacI/BamHI blunt fragment from the pVIP4CAT sequence into the EcoRI/BamHI blunt sites of p⌬E1sp1B.
Construction and propagation of recombinant adenoviruss
Recombinant adenoviruss (adenovirus type 5) were constructed by in vivo recombination of plasmids in 293 cells using adenovirus vector construction kit C (Microbix Biosystems, Toronto, Canada). p⌬E1SP1A and p⌬E1SP1B contain the left-hand end of adenovirus type 5 (from base pair 22 (0 map units) (m.u.) to base pair 5790 (16.1 m.u.)), with a deletion of E1 sequences from base pair 342 to base pair 3523 (1.0 -9.8 m.u.), but containing the entire packaging signal. A multicloning site is present in the E1 region, allowing for insertion of the foreign gene. p⌬E1SP1A and p⌬E1SP1B are identical except for the orientation of the multicloning site between ClaI and BglII. The pBHG10 plasmid contains the rest of the adenovirus type 5 genome and a small overlapping region with both p⌬E1sp1A and p⌬E1sp1B to allow recombination after cotransfection into 293 cells.
42 pBHG10 is noninfectious due to lack of a packaging signal needed for encapsidation of viral DNA; 43 in addition, to allow a bigger insert, the nonessential E3 region (78.3-85.8m.u.) is deleted. Low-passage 293 cells (Ͻ40 passages) in a 60-mm dish were set up at 50% confluence. A total of 10 g of p⌬E1(Ϫ71A), p⌬E1(Ϫ42A), p⌬E1(25A), or p⌬E1(VIPB) and 10 g of pBHG10 were then cotransfected into the cells by calcium phosphate precipitation. Medium was renewed the following day and on reaching confluence, the cells were trypsinized and diluted. On release from the cells, recombinant viruses were confirmed by polymerase chain reaction analysis of isolated viral DNA and titrated on 293 cells. Purification of viral DNA was performed as follows. Infected 293 cells were harvested and lysed by the addition of 400 L of lysis buffer (20 mM of Tris-Cl (pH 7.5), 0.5% Nonidet P-40, 500 mM NaCl, and 1 mM dithiothreitol) on ice for 5 minutes. After centrifugation for 5 minutes in a microfuge, the supernatant was adjusted by the addition of 15 L of 20% sodium dodecyl sulfate and 150 g of proteinase K and incubated at 55°C for 30 minutes. The sample was then phenol-extracted, ethanol-precipitated, and finally treated with 20 g/mL ribonuclease A for 30 minutes to remove the RNA.
Cell culture and adenovirus infections
The JEG3, 44 Su-ccs-1, 11 and DTC1 30 cells lines were maintained as monolayers in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum. PC12 cells were maintained as monolayers in DMEM containing 10% fetal calf serum and 5% horse serum. RAT1 is a rat embryo fibroblast cell line and MEL28 is a human melanoma cell line. Polymerase chain reaction analysis of genomic DNA confirmed the presence of the SomTK fusion gene in each clone (data not shown). Conditions for adenovirus infections were as follows: Cells in a 60-mm culture dish at ϳ50% confluence were infected at a multiplicity of infection (MOI) as indicated in the figure legend. adenovirussorption of the virus was carried out in 0.5 mL of DMEM buffered with 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.2) for 45 minutes, followed by dilution with fresh growth media.
Transfections, CAT assays, and RNA analysis All transfections were carried out by calcium phosphate coprecipitation, and CAT assays were performed as described previously. 45 Precipitates contained 5 g of reporter plasmid, the indicated amount of activator plasmid(s), and 20 g of total DNA made up with pSP64 as carrier. One-third of the precipitate was added to ϳ50% confluent JEG3 cells in a 60-mm culture dish. For quantitation of results, the percentage of conversion of unacetylated to acetylated 14 C-chloramphenicol under linear assay conditions was determined by excision of spots from the thin-layer chromatography plate and quantitation of radioactivity using a liquid scintillation counter. Preparation of total cellular RNA and detection of specific transcripts by primer extension was as described previously. 46 
Production of DTC1 transfectants and ganciclovir (GCV) sensitivity assays
A 50% confluent monolayer of DTC1 cells (ϳ2.5 ϫ 10 6 cells) was transfected by calcium phosphate coprecipitation 39 with 5 g of the desired plasmid with or without 1 g of polyneo plasmid, conferring neomycin resistance. DTC1 cells were used because Su-ccs-1 cells do not yield viable colonies due to a very low transfection efficiency and/or cytotoxicity at low cell density (K.A.W.L., unpublished observation). Transfected cells were washed with phosphate-buffered saline, and old medium was replaced by fresh growth medium at 1 day posttransfection. Cells were then split to 25% confluence into medium with 400 g/mL G418 (Life Technologies, Gaithersburg, Md; stored as 40 mg/mL in sterile-filtered 100 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.2)). Selection medium was changed daily for the first 10 days and every 2 days afterward. Cells were set up in duplicate at 30% confluence in 24-well plates the day before the addition of GCV (Cymevene, 500 mg GCV/546 mg from Ben Venue Laboratories, Bedford, Ohio, under license from Syntex Laboratories, Palo Alto, Calif) to the growth medium. GCV was dissolved in autoclaved H 2 O at a concentration of 0.5 mg/mL and stored at 4°C. Appropriate drug concentrations were made by diluting the stock solution with fresh medium immediately before each experiment. The same volume of medium was added for the control experiment, medium was changed every 2 days, and viable cell counts were taken using trypan blue exclusion and a hemocytometer.
RESULTS
Cytotoxic prodrug treatment of DTC1 cells in vitro
A truncated version of the somatostatin promoter (hereafter simply referred to as the somatostatin promoter) containing promoter sequences to Ϫ71 including a single ATF-binding site, is highly active when transiently introduced into both MMSP cell lines (DTC1 and Su-ccs-1). 30 We wanted to test the ability of a somatostatin promoter-hsvtk fusion gene to express hsvtk in the above cells and thereby confer sensitivity to the cytotoxic prodrug GCV. To establish a test system for GCV sensitivity, we produced DTC1 transfectants containing a stably integrated somatostatin promoter linked to CAT as a reporter. Initially, we used CAT instead of hsvtk as a simpler test for somatostatin promoter activity under the desired conditions. Two pools of DTC1-derived stable transfectants (D42 and D71) were obtained after G418 selection. D42 represents a pool of DTC1 cells containing the ⌬(Ϫ42)SomCAT fusion gene (lacking the ATF-binding site in the somatostatin promoter); D71 represents a pool of cells containing the ⌬(Ϫ71)SomCAT fusion gene (containing the ATF site). Somatostatin promoter activity was assessed by CAT assay (Fig 1A) . Similar to results obtained in transient assays, 30 there was no detection of somatostatin promoter activity in D42 cells (or parental DTC1 cells), whereas strong activity was obtained in D71 cells. PC12 cells containing a stably integrated cAMP-inducible VIP promoter linked to CAT serve as a comparison for activated levels of transcription. In the presence of 20 M forskolin (which increases intracellular cAMP levels), the VIP promoter was activated in PC12 cells to a level that was similar to that seen for the somatostatin promoter in D71 cells. The above results show that (on average within a pool of transfectants) chromosomal copies of the somatostatin promoter are active in DTC1 cells. Promoter activity is dependent upon the ATFbinding site, consistent with the promoter being activated by endogenous EWS/ATF1.
We produced stable transfectants from DTC1 cells containing somatostatin promoter-hsvtk cDNA fusions and tested their sensitivity to GCV. GCV is nontoxic and is converted into a cytotoxic DNA synthesis chain terminator by hsvtk. D71TK and D42TK represent pools of transfectants similar to D71 and D42 cells, except that the CAT reporter is replaced by hsvtk cDNA. In the absence of GCV, D71TK cells exhibit the same growth kinetics as parental DTC1 cells (Fig 1B) . adenovirusding GCV (5 g/mL) to the cell culture medium has no effect on the survival of parental DTC1 cells but severely inhibits the growth of D71TK cells, starting at day 4 and ending in cell death by day 12. Individual G418-resistant clones were isolated and tested for sensitivity to GCV (Fig 1C) . Three independent clones (711, 714, and 716) isolated from D71TK cells and three independent clones (422, 423, and 424) isolated from D42TK cells were examined. After treatment with 0.1 g/mL GCV for 10 days, the survival rates of clone 716 (48%), clone 714 (38%), and clone 711 (35%) were lower than the survival rates of all three clones (422, 423, and 424, average survival of 97%) from D42TK cells. At 0.3 g/mL GCV, the survival rates at 10 days for 716 (8% survival), 714 (5%), and 711 (5%) were quite low, whereas the survival of 422, 423, and 424 was only slightly affected (average of 95%). Thus, D71TK cells are sensitive to GCV at concentrations previously reported to be toxic for other )) is shown. B: GCV sensitivity of DTC1 cells containing a somatostatin-hsvtk fusion gene. Growth curves are shown for parental DTC1 cells or for a pool of stable DTC1 transfectants (D71TK) containing a stably integrated somatostatin-hsvtk fusion gene. GCV was included in the cell culture medium at a concentration of 5 g/mL. C: GCV sensitivity of individual transfectants. Cells were treated with the indicated concentrations of GCV, and cell survival was determined by viable cell counting after 10 days of GCV treatment. Three independent clones (711, 714, and 716) isolated from D71TK cells and three independent clones (422, 423, and 424) isolated from D42TK cells were examined. Survival rates for the three control (EWS/ATF1-negative) cell lines (MEL28, JEG3, and RAT1) are also shown.
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hsvtk-expressing tumor cells. 35, 47 As an additional test of specificity, we examined the effect of GCV (after introduction of the SomTK fusion gene) in three other mammalian cell lines (MEL28, JEG3, and RAT1) that do not express EWS/ATF1 (Fig 1C) . Similar to clones 422, 423, and 424, MEL28 (90% survival), JEG3 (87%), and RAT1 (85%) were all only slightly affected by GCV treatment. In summary, the above results show that a somatostatin promoter-hsvtk fusion can confer GCVdependent cytotoxicity to DTC1 cells. This effect is cell-specific and (as indicated by the requirement for the ATF site in the somatostatin promoter) most likely results from somatostatin promoter activation by endogenous EWS/ATF1.
Design of recombinant adenoviruss for toxic gene delivery
In a transient cotransfection assay EWS/ATF1 can activate several promoters that contain ATF-binding sites. 30 Trans-activation of four such promoters by exogenous EWS/ATF1 in JEG3 cells is shown (Fig 2A) . VIP25CAT (containing the cAMP-response-element from the VIP promoter linked to the RSV TATA box), VIP4CAT (containing the intact VIP promoter to position Ϫ94), and ⌬(Ϫ71)SomCAT are all strongly trans-activated (ϳ100-fold) by EWS/ATF1. In addition, the adenovirus E3 promoter, which contains an ATF site required for trans-activation by cAMP, 48 -50 is strongly activated by EWS/ATF1 in this assay (Fig 2A) . We constructed recombinant adenoviruss containing the above promoters (and a control virus derived from ⌬(Ϫ42)SomCAT) linked to CAT (Fig 2B) . Again, we initially used CAT instead of hsvtk as a simpler test for promoter activity, and we refer to the above promoters (AD71, AD42, AD25V, and ADVIP) as virus-borne ATF-dependent promoters (VAPs).
VAP activity during adenovirus infection DTC1 and Su-ccs-1 were infected with AD71 and AD42 at different MOIs, and CAT assays performed at 48 hours postinfection (hpi) (Fig 3A) . At MOIs up to 100 (or 1000, data not shown), both AD71 and AD42 showed no detectable promoter activity in DTC1 or Su-ccs-1 cells. Using the transient assay described previously, 30 we tested the ability of the DTC1 cells used in the above experiment to support activation of the somatostatin promoter (Fig 3B) . As shown previously, 30 the somatostatin promoter has high activity in DTC1 cells (comparable or greater than the activity of the SV40 and RSV promoters) compared with the near background levels observed in JEG3 cells (that lack endogenous EWS/ATF1). Thus, the lack of VAP activity observed in DTC1 cells is not due to loss of trans-activation capacity of the batch of DTC1 cells used. To confirm the integrity of the recombinant viruses, to test their infectivity, and to test whether activators other than EWS/ATF1 can activate VAPs, we infected 293 cells with AD42 and AD71 and analyzed VAP activity by CAT assay ( Fig  3A) . 293 cells are useful for the above purposes because they express an endogenous adenovirus E1A gene that is an activator of many ATF-dependent promoters. 46, 48 For AD71, promoter activity is readily detectable at low MOIs and reaches a maximum at an MOI of between 20 and 100 (14.7% conversion in the CAT assay at an MOI of 100). For AD42, promoter activity was also detectable and saturated at an MOI of between 100 and 400 (1.4% conversion at an MOI of 400). The maximal promoter activity for AD71 is therefore ϳ10-fold higher than AD42. The results show that AD42 and AD71 are infectious in 293 cells, and that the somatostatin promoter can be activated in these cells either by E1A or by other viral activators produced during a viral infection. Similar to AD42 and AD71, AD25V and ADVIP exhibited no VAP activity in either DTC1 or Su-ccs-1 cells, Fig  2) were used to infect DTC1, Su-ccs-1, and 293 cells at different MOIs. CAT assays were performed at 48 hpi unless otherwise indicated, and representative autoradiograms of CAT assays are shown. B: Transactivation using DTC1 cells in a transient assay. Test promoters were assayed after the transfection of DTC1 and JEG3 cells. Transfection conditions were as described in the legend to Figure 2 , and the same precipitate for each test promoter was evenly divided and added to either DTC1 and JEG3 cells. CAT assays were performed at 40 hours posttransfection.
LUNG AND LEE: GENE THERAPY FOR MMSP
whereas VAP activity was readily detected after infection of 293 cells (Fig 3A) . Thus, the inability of endogenous EWS/ATF1 to activate VAPs in MMSP cells does not reflect a general repression of VAPs in infected cells.
Viral replication and gene expression in MMSP cells
The low activity of VAPs in MMSP cells could be caused either by inefficient delivery of adenovirus to the nucleus of MMSP cells or the inability of EWS/ATF1 to activate transcription in the context of viral chromatin. To distinguish between these possibilities, we examined viral replication and gene expression in MMSP cells (Fig 4) . Replication of wild-type (WT) adenovirus serves as a positive control for normal (E1A-dependent) replication, and an E1A-negative virus (dl312) is very similar to the recombinant viruses (AD42, AD71, ADVIP, and AD25V) used in our gene transfer experiments. Cells were infected for virus replication experiments, and the virus produced was quantitated by plaque assay at different times after infection (Fig 4A) . As a control for viral infections and plaque assays, 293 cells were included. WT virus propagates to high titer in 293 cells, and due to the presence of endogenous E1A in these cells, the replication of an E1A mutant virus (dl312) is similar to WT virus. Replication in 293 cells confirms the presence of infectious viruses for the experiments in MMSP cells. For both DTC1 and Su-ccs-1 cells, WT virus replicates to high titer (comparable with 293 cells), although the kinetics of replication are delayed relative to 293 cells. Maximal levels of virus production take 4 days for both DTC1 and Su-ccs-1 cells but only 2 days for 293 cells. As expected, dl312 showed limited ability to replicate in both DTC1 and Su-ccs-1 cells, and cell viability was not obviously affected even after 14 days of infection with dl312. The inability of dl312 to replicate in At different times after infection, culture medium and remaining cells were freeze/thawed three times, the debris was removed by centrifugation, and viral titers were determined by plaque assay using 293 cells. B: E3 gene expression during adenovirus infection of MMSP cells. DTC1 and Succs-1 cells were infected with WT adenovirus (unless otherwise indicated) at different MOIs or for different times (as indicated above). Total RNA was extracted, and correctly initiated E3 transcripts (indicated to the side) were detected by primer extension using 32 Plabeled primers as described in Materials and Methods. Experiments were repeated twice. C: Trans-activation of the somatostatin promoter by WT adenovirus. DTC1 or 293 cells were infected with recombinant AD71 virus (MOI ϭ 100) in the absence or presence of WT adenovirus (MOI ϭ 50). CAT assays were performed at 24 hpi, and a representative CAT assay is shown. Experiments were repeated twice.
MMSP cells indicates that the E1A-negative recombinant viruses used in our experiments do not replicate in MMSP cells.
Consistent with the efficient replication of adenovirus in MMSP cells, the viral E1A protein is expressed in the nucleus (data not shown); in addition, we have shown previously that two adenovirus early promoters (E2 and E3) are active during a WT infection of MMSP cells, depending upon the viral E1A protein (Ref. 51, Fig 4B) . To further characterize the behavior of adenovirus during infection of MMSP cells, we examined E3 promoter activity in more detail. Consistent with the delayed kinetics of viral replication in MMSP cells, the E3 promoter is also activated later than in 293 cells. In 293 cells, the E3 promoter is typically activated at ϳ6 hpi, whereas in MMSP cells the promoter has only low activity at 20 hpi and is strongly activated only at later times (between 20 and 40 hpi). Titration experiments using different MOIs show that E3 gene expression is saturated at a relatively low MOI (saturation is reached at an MOI of Ͻ20, Fig 4B) , indicating that MMSP cells take up the virus efficiently. The late onset of E3 gene expression is therefore probably not due to inefficient uptake of virus, but more likely reflects delayed kinetics for early viral gene expression. Because the E3 promoter contains an ATF1-binding site and is strongly activated by EWS/ATF1 in the transient assay (see Fig 2A) , it is also of significance that, like other VAPs, the E3 promoter is not activated by endogenous EWS/ATF1 in the context of a viral chromatin.
Taken together, the above data indicate that VAPs are effectively delivered to the nucleus of MMSP cells but that endogenous EWS/ATF1 is unable to activate these promoters. To test whether VAPs are generally repressed or whether they are specifically refractory to activation by EWS/ATF1, we asked whether E1A (which can activate VAPs in 293 cells (Fig 3A) ) can activate VAPs in MMSP cells (Fig 4C) . DTC1 cells were coinfected with WT adenovirus (containing E1A) and AD71, and CAT assays were performed at 24 hpi. Infection of 293 cells with AD71 was performed as a positive control for viral infection and CAT assays. As shown earlier, AD71 infection alone produces no detectable promoter activity in DTC1 cells, whereas coinfection with WT virus results in significant promoter activation. Thus, E1A protein (or possibly some other viral proteins) can activate VAPs in DTC1 cells. Activation during viral infection of DTC1 cells is not as great as that observed in 293 cells. This might reflect a lower ability of E1A to activate in DTC1 cells or the delayed kinetics for VAP activation as shown for the E3 promoter (Fig 4B) . In summary, the above results show that the inability of EWS/ATF1 to activate VAPs is not due to a general repression mechanism (because E1A can activate VAPs), but rather is specific for EWS/ATF1 and/or MMSP cells.
DISCUSSION
We have evaluated the use of tumor-specific promoters and an adenovirus vector for cytotoxic prodrug treatment of MMSP tumor cells in vitro. Using an integrated somatostatin promoter linked to hsvtk, GCV sensitivity can be conferred to DTC1 cells. This cytotoxic effect is specific for DTC1 cells and requires the ATF-binding site in the somatostatin promoter, indicating that cytotoxicity is caused by EWS/ATF1. The finding that the somatostatin promoter can be activated in MMSP cells (presumably by EWS/ATF1) when present in a chromosomal context is significant, because D71TK cells provide a cell system for the further evaluation of the cytotoxic prodrug approach for MMSP therapy. For example, in the future, D71TK cells can be used for tumor production in nude mice and subsequent testing of GCV sensitivity of tumors in intact animals. The above findings indicate that the somatostatin-hsvtk fusion tested (or hsvtk fusions to other promoters that are strongly activated by EWS/ATF1) has great potential for cytotoxic prodrug treatment of MMSP tumor cells in vivo.
In contrast to previous studies that exploited adenovirus as a vector for cellular promoters, 35, 36, [52] [53] [54] [55] promoters that can be activated by EWS/ATF1 in transient assays are not activated in the context of adenovirus chromatin. VAPs are efficiently delivered to the nucleus of MMSP cells but cannot be activated by EWS/ATF1. Therefore, our findings indicate that first-generation adenovirus vectors (such as the one used in our study) may have limited potential as a gene delivery vehicle for cytotoxic prodrug treatment of MMSP cells.
The reason for the inability of EWS/ATF1 to activate VAPs is unclear. A variety of VAPs are refractory to EWS/ATF1 and (as far as our studies go) this block is not restricted to position or orientation within the viral genome. In addition, the inability of EWS/ATF1 to activate resident viral promoters (E3 and probably E2) indicates that the lack of response of cellular promoters is not due to the absence of putative cis elements that are required for transcription in adenovirus chromatin. Efficient replication of adenovirus together with E3 promoter activation in MMSP cells demonstrates that these cells can support E1A-dependent transcription of VAPs. Therefore, our results are consistent with an inability of EWS/ATF1 to activate VAPs. In infected cells, viral chromatin is thought to be a distinct nucleoprotein complex (the adenovirus-core) containing the viral core proteins VII and V. 56 In vitro transcription from adenovirus-core templates is repressed and requires a protein, template-activating factor-1, which has been suggested to modify the adenovirus-core to allow functional interactions with both replication and transcription factors. 57 Therefore, it is possible that, in the absence of E1A, template-activating factor-1 (or other similar factors) is unable to modify the adenovirus-core, resulting in a block to activation by EWS/ATF1. However, such an effect would be relatively specific for EWS/ATF1 and/or MMSP cells, because many other promoters can be activated by their corresponding cellular activators (independently of E1A) when present in the adenovirus-core. 35, 36, [52] [53] [54] [55] Future in vitro studies will be required to test the effect of adenovirus-core templates on trans-activation by EWS/ATF1. Irrespective of the protein factors involved, it is likely that cis-acting viral DNA sequences play a role (indirectly, due to their implied role in viral chromatin assembly) in preventing VAPs being activated by EWS/ ATF1. Therefore, it is possible that vector modification could overcome the effect. The use of larger regions of EWS/ATF1-dependent promoter sequences instead of the small truncated promoters used in our study is one option. Second-generation adenovirus vectors 58, 59 containing less of the viral genome enable this possibility to be tested by allowing larger foreign DNA inserts. Another option would be to test so called "gutless vectors" lacking all adenovirus genes. 60, 61 If the adenovirus-core proteins involved in viral chromatin assembly are indeed responsible for inhibiting EWS/ATF1, then the use of gutless vectors should overcome this problem.
Other novel therapies being developed for EWSrelated sarcomas focus on inhibiting the function of EFPs inside the tumor cells. For Ewing's sarcoma, expression of antisense RNA to EWS/Fli1 transcripts can successfully lower tumorigenicity. 21, 23, 24 In addition, the development of small molecule inhibitors that target the EAD is an attractive long-term option. The EAD has a highly repetitive primary structure 4, 32 and makes distinctive contacts with the transcriptional machinery, 62, 63 indicating that the EAD is a likely target for small molecule inhibitors. However, because it is currently not known whether EWS/ATF1 is required for MMSP tumor maintenance, the potential that EAD inhibitors would hold for MMSP therapy is unclear. In view of this, the properties that we have described for tumor-specific EWS/ATF1-dependent promoters suggest that approaches to cytotoxic prodrug therapy for MMSP should be pursued. Currently, the main advantage of this approach is that it relies simply on the well-characterized tumor specificity and potent trans-activation properties of EWS/ATF1 without regard for the role of EWS/ATF1 in tumorigenesis. The use of second-generation Ad vectors or other methods 29, 34 for toxic gene delivery to MMSP cells remains a priority.
